[{"orgOrder":0,"company":"Atamyo Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"ATA-100","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Atamyo Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atamyo Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Atamyo Therapeutics \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Financing will support the Phase 2 Alpestria-1 study and profiling of EYP001 (vonafexor), a selective NR1H4 agonist, in Autosomal Dominant Polycystic Kidney Disease (ADPKD).

                          Product Name : EYP001

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 01, 2024

                          Lead Product(s) : Vonafexor

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : OrbiMed Advisors

                          Deal Size : $42.5 million

                          Deal Type : Series C Financing

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : ATA-100 (GNT0006), a single-administration gene therapy candidate for LGMD2I/R9, delivers a normal copy of the gene for production of FKRP proteins, which is investigated for the treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9).

                          Product Name : ATA-100

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 09, 2023

                          Lead Product(s) : ATA-100

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Proceeds from the financing will be used to fund the first-in-human trials of the Company’s two lead gene-independent assets, SPVN06 and SPVN20, as well as the development of genome editing assets through its collaboration with Intellia Therapeutics.

                          Product Name : SPVN06

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 14, 2022

                          Lead Product(s) : SPVN06

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Jeito Capital

                          Deal Size : $75.0 million

                          Deal Type : Series B Financing

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : SPVN06 is a proprietary, mutation-agnostic, AAV gene therapy approach comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of cone photoreceptors.

                          Product Name : SPVN06

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          January 12, 2022

                          Lead Product(s) : SPVN06

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : First regulatory authorization to initiate this global, multi-center, single-arm, two-stage, adaptive-design clinical trial of LYS-GM101 in patients with a diagnosis of early or late infantile GM1 gangliosidosis.

                          Product Name : LYS-GM101

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          November 01, 2021

                          Lead Product(s) : LYS-GM101

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Proceeds from the financing will be primarily used to advance the development of SparingVision’s breakthrough treatment SPVN06 for the mutation-agnostic treatment of retinitis pigmentosa.

                          Product Name : SPVN06

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          October 21, 2020

                          Lead Product(s) : SPVN06

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : 4BIO Capital

                          Deal Size : $51.9 million

                          Deal Type : Financing

                          blank